Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(10 sites)

United States

Mayo Clinic Hospital in Arizona, Phoenix, Arizona

UC Irvine Health Cancer Center-Newport, Costa Mesa, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

Mayo Clinic in Florida, Jacksonville, Florida